https://www.selleckchem.com/pr....oducts/pnd-1186-vs-4
ry tumor discordance. Overall, tumor subtype switching and its effect on clinical management remains underappreciated.Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3+ regulatory T-cell frequencies among CD4+ T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4+ Foxp3+ regulatory T-cell frequencies in
Like
Comment
Share
